Valganciclovir is a mono-valyl ester prodrug of ganciclovir that is orally bioavailable and is well absorbed in the gastrointestinal system. Valganciclovir is an antiviral compound that, like ganciclovir, is an analog of 2’-deoxy-guanosine that is incorporated into DNA by viral DNA polymerase, preventing chain elongation. This compound is used to treat cytomegalovirus (CMV) in newborns and adults and may also exhibit benefit in the treatment of Kaposi sarcoma flares.
| Cas No. | 175865-59-5 |
|---|---|
| Purity | ≥98% |
| Formula | C14H22N6O5 • HCl |
| Formula Wt. | 354.36 |
| IUPAC Name | [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl](2S)-2-amino-3-methylbutanoate;hydrochloride |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | V0244 Info Sheet PDF |
|---|
Stronati M, Lombardi G, Garofoli F, et al. Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection. Curr Drug Metab. 2013 Feb;14(2):208-15. PMID: 22935067.
Iwasenko JM, Scott GM, Rawlinson WD, et al. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J Med Virol. 2009 Mar;81(3):507-10. PMID: 19152402.
Pantanowitz L, Früh K, Marconi S, et al. Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol. 2008 Jul 23;8:7. PMID: 18651955.
